DK3216784T3 - Fremgangsmåde til fremstilling af histamin-h3-receptor-modulatorer - Google Patents
Fremgangsmåde til fremstilling af histamin-h3-receptor-modulatorer Download PDFInfo
- Publication number
- DK3216784T3 DK3216784T3 DK17151754.3T DK17151754T DK3216784T3 DK 3216784 T3 DK3216784 T3 DK 3216784T3 DK 17151754 T DK17151754 T DK 17151754T DK 3216784 T3 DK3216784 T3 DK 3216784T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- formula
- group
- range
- molar equivalents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (6)
1. Fremgangsmåde til fremstilling afen forbindelse med formel (l-E)
hvori R1 er valgt fra gruppen, der består af Ci-4-alkyl og C3-io-cycloalkyl; m er 2; R2 er valgt fra gruppen, der består af -OCHR3R4 og -Z-Ar; R3 er hydrogen og R4 er en C3-io-cycloalkyl eller heterocycloalkylring; hvor C3-io-cycloalkyl eller heterocycloalkylringen er usubstitueret eller substitueret med -Ci-4-alkyl eller acetyl; alternativt, danner R3 og R4 sammen med det carbon, hvortil de er bundet, en C3-io-cycloalkyl eller heterocycloalkylring; hvor C3-io-cycloalkyl eller heterocycloalkylringen er usubstitueret eller substitueret med -C1-4-alkyl eller acetyl; Z er valgt fra gruppen, der består af S og O; Ar er en phenyl eller heteroaryl; hvor phenyl eller heteroarylen er usubstitueret eller substitueret med en, to eller tre R5-substituenter; hvor hver R5-substituent er uafhængigt valgt fra gruppen, der består af halogen, -Ci-4-alkyl, -OH, -OCi-4-alkyl, -SCi-4-alkyl, -CN, -CONRaRb, og -NO2; og hvor Ra og Rb er hver uafhængigt -H eller -Ci-4-alkyl; eller et farmaceutisk acceptabelt salt, et farmaceutisk acceptabelt prodrug deraf, hvor "prodrug" refererer til forbindelser med en aminosyre-rest eller en polypeptidkæde af to eller flere aminosyrerester, der er covalent forbundet gennem en amid- eller esterbinding til en fri amino-, hy-
droxyl- eller carboxylsyregruppe af en forbindelse med formel (l-E); forbindelser der er fremstillet ved derivatisering af frie hydroxylgrupper ved anvendelse af grupper, der indbefatter hemisuccinater, phosphatestere, dimethylaminoacetaterog phosphoryloxymethyloxycarbonyler; carba-matderivater af hydroxyl- og aminogrupper; carbonatderivater, sulfonate-stere og sulfatestere af hydroxylgrupper; forbindelser der er fremstillet ved derivatisering af hydroxylgrupper som (acyloxy)methyl- og (acyloxy)ethylethere, hvor acylgruppen kan være en alkylester, der eventuelt er substitueret med en eller flere ether-, amin- eller carboxylsyre-funktionaliteter, eller hvor acylgruppen er en aminosyreester og forbindelser der er fremstillet ved derivatisering af frie aminer som amider, sulfonamider eller phosphonamider; hvilken fremgangsmåde omfatter:
at omsætte en forbindelse med formel (V-S) med et aldehyd- eller ketonderivat af den ønskede R1-substituentgruppe; pur eller i et organisk opløsningsmiddel for at opnå den tilsvarende forbindelse med formel (IX);
at omsætte forbindelsen med formel (IX) med en forbindelse med formel (VI), hvor LG1 er en første leavinggruppe og LG2 er en leavinggruppe; i nærvær af et reduktionsmiddel; i et organisk opløsningsmiddel; til at opnå den tilsvarende forbindelse med formel (X-E);
at omsætte forbindelsen med formel (X-E) med en forbindelse med formel (XII); i nærvær af en første uorganisk base; i et organisk opløsningsmiddel; eller at omsætte forbindelsen med formel (X-E) med en forbindelse med formel (XIII); i nærvær af en anden uorganisk base; i et organisk opløsningsmiddel; for at give den tilsvarende forbindelse med formel (l-E).
2. Fremgangsmåden ifølge krav 1, hvor R1 er cyclobutyl, m er 2 og R2 er valgt fra gruppen, der består af 4-fluorphenyl, 3-cyanophenyl, 4-tetrahydropyranyl, LG1 er chlor og LG2 er chlor.
3. Fremgangsmåden ifølge krav 1, hvor R1 er cyclobutyl.
4. Fremgangsmåden ifølge krav 1, hvor R2 er -OCHR3R4, og R3 og R4 sammen med det carbon, hvortil de er bundet, danner tetrahydropyranyl, eller hvor R2 er -Z-Ar og Ar er valgt fra gruppen, der består af 3-cyanophenyl eller 4-fluorphenyl.
5. Fremgangsmåden ifølge krav 1, hvor LG1 er chlor og LG2 er chlor.
6. Fremgangsmåden ifølge krav 1 til fremstilling af en forbindelse med formlen (l-E) eller et farmaceutisk acceptabelt salt deraf.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16117709P | 2009-03-18 | 2009-03-18 | |
EP10722449.5A EP2429996B1 (en) | 2009-03-18 | 2010-03-17 | Process for the preparation of histamine h3 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3216784T3 true DK3216784T3 (da) | 2019-04-08 |
Family
ID=42315639
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17151754.3T DK3216784T3 (da) | 2009-03-18 | 2010-03-17 | Fremgangsmåde til fremstilling af histamin-h3-receptor-modulatorer |
DK10722449.5T DK2429996T3 (en) | 2009-03-18 | 2010-03-17 | Process for the preparation of histamine h3 receptor modulators |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10722449.5T DK2429996T3 (en) | 2009-03-18 | 2010-03-17 | Process for the preparation of histamine h3 receptor modulators |
Country Status (18)
Country | Link |
---|---|
US (4) | US8748596B2 (da) |
EP (3) | EP3216784B1 (da) |
JP (1) | JP5642149B2 (da) |
CN (1) | CN102428070B (da) |
AU (1) | AU2010226711B2 (da) |
CA (2) | CA2755335C (da) |
CY (2) | CY1119437T1 (da) |
DK (2) | DK3216784T3 (da) |
ES (2) | ES2625261T3 (da) |
HR (2) | HRP20170776T1 (da) |
HU (2) | HUE044837T2 (da) |
LT (2) | LT2429996T (da) |
MX (3) | MX347775B (da) |
PL (2) | PL3216784T3 (da) |
PT (2) | PT3216784T (da) |
SI (2) | SI2429996T1 (da) |
TR (1) | TR201902858T4 (da) |
WO (1) | WO2010107897A2 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8748596B2 (en) | 2009-03-18 | 2014-06-10 | Janssen Pharmaceutica Nv | Process for the preparation of histamine H3 receptor modulators |
KR101427221B1 (ko) * | 2012-08-29 | 2014-08-13 | 주식회사 에스텍파마 | 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법 |
CN104447867B (zh) * | 2013-09-17 | 2017-12-26 | 江苏天士力帝益药业有限公司 | 一种噻吩并哌啶衍生物、制备方法及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5724346B2 (da) * | 1973-06-22 | 1982-05-24 | ||
NZ576432A (en) * | 2002-10-23 | 2010-06-25 | Janssen Pharmaceutica Nv | Piperazinyl and diazapanyl benzamides and benzthioamides |
AU2007256931B2 (en) | 2006-05-30 | 2013-01-24 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
KR101546712B1 (ko) * | 2007-11-20 | 2015-08-24 | 얀센 파마슈티카 엔.브이. | 히스타민 h3 수용체의 조절제로서 사이클로알킬옥시- 및 헤테로사이클로알킬옥시피리딘 화합물 |
US8748596B2 (en) | 2009-03-18 | 2014-06-10 | Janssen Pharmaceutica Nv | Process for the preparation of histamine H3 receptor modulators |
-
2010
- 2010-03-17 US US13/257,224 patent/US8748596B2/en active Active
- 2010-03-17 EP EP17151754.3A patent/EP3216784B1/en active Active
- 2010-03-17 MX MX2014015305A patent/MX347775B/es unknown
- 2010-03-17 PL PL17151754T patent/PL3216784T3/pl unknown
- 2010-03-17 DK DK17151754.3T patent/DK3216784T3/da active
- 2010-03-17 PT PT17151754T patent/PT3216784T/pt unknown
- 2010-03-17 SI SI201031474T patent/SI2429996T1/sl unknown
- 2010-03-17 ES ES10722449.5T patent/ES2625261T3/es active Active
- 2010-03-17 CA CA2755335A patent/CA2755335C/en active Active
- 2010-03-17 MX MX2016007228A patent/MX349489B/es unknown
- 2010-03-17 WO PCT/US2010/027638 patent/WO2010107897A2/en active Application Filing
- 2010-03-17 PL PL10722449T patent/PL2429996T3/pl unknown
- 2010-03-17 EP EP18194673.2A patent/EP3492451B1/en active Active
- 2010-03-17 AU AU2010226711A patent/AU2010226711B2/en not_active Ceased
- 2010-03-17 PT PT107224495T patent/PT2429996T/pt unknown
- 2010-03-17 EP EP10722449.5A patent/EP2429996B1/en active Active
- 2010-03-17 DK DK10722449.5T patent/DK2429996T3/da active
- 2010-03-17 TR TR2019/02858T patent/TR201902858T4/tr unknown
- 2010-03-17 MX MX2011009784A patent/MX2011009784A/es active IP Right Grant
- 2010-03-17 LT LTEP10722449.5T patent/LT2429996T/lt unknown
- 2010-03-17 CN CN201080022339.1A patent/CN102428070B/zh active Active
- 2010-03-17 SI SI201031867T patent/SI3216784T1/sl unknown
- 2010-03-17 CA CA2965059A patent/CA2965059C/en active Active
- 2010-03-17 ES ES17151754T patent/ES2714852T3/es active Active
- 2010-03-17 JP JP2012500921A patent/JP5642149B2/ja active Active
- 2010-03-17 HU HUE17151754 patent/HUE044837T2/hu unknown
- 2010-03-17 HU HUE10722449A patent/HUE032345T2/en unknown
- 2010-03-17 LT LTEP17151754.3T patent/LT3216784T/lt unknown
-
2014
- 2014-04-25 US US14/261,713 patent/US9518021B2/en active Active
-
2016
- 2016-11-11 US US15/349,521 patent/US9809547B2/en active Active
-
2017
- 2017-05-24 HR HRP20170776TT patent/HRP20170776T1/hr unknown
- 2017-05-26 CY CY20171100547T patent/CY1119437T1/el unknown
- 2017-10-04 US US15/724,711 patent/US10323002B2/en active Active
-
2019
- 2019-03-11 HR HRP20190476TT patent/HRP20190476T1/hr unknown
- 2019-03-12 CY CY20191100292T patent/CY1121556T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080045507A1 (en) | Substituted benzamide modulators of the histamine h3 receptor | |
US20090131417A1 (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
US10323002B2 (en) | Process for the preparation of histamine H3 receptor modulators | |
EP2222664B1 (en) | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor | |
WO2008109333A1 (en) | Indole and benzothiophene compounds as modulators of the histamine h3 receptor | |
AU2015221574A1 (en) | Process for the preparation of histamine H3 receptor modulators | |
US20090131416A1 (en) | Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor |